The targeted, safe and effective delivery of advanced nucleic acid therapeutics has proven to be a significant block in the clinical application of transformative therapies. TargoPep is working to address this challenge by providing unique delivery solutions based on advanced delivery peptide (ADP) technologies. TargoPep ADPs utilise tuned, bespoke structures to address the fundamental problem of inadequate cellular recognition and penetration to complete and enable the next generation of gene therapies. TargoPep will partner with biopharmaceutical clients to provide unique solutions to their complex delivery challenges to produce blockbusting gene therapeutics that offer the promise of cure over disease management.